Skip to content

Author

Vincent Cottin

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Protocol and rationale for a randomised, double-blind, placebo-controlled phase 3 trial of admilparant (BMS-986278), an oral lysophosphatidic acid receptor 1 antagonist, in patients with idiopathic pulmonary fibrosis: ALOFT-IPF

Abstract Introduction Idiopathic pulmonary fibrosis (IPF) is associated with progressive loss of lung function and poor prognosis. There remains a need for novel therapies for patients with IPF. Admilparant, an oral lysophosphatidic acid receptor 1 antagonist, slowed lung function decline and was well tolerated in a ph...

Toby M. Maher, Fernando J. Martinez, M. Kreuter et al. · 0 citations
Open access Jul 2026

Prevalence, detection, and trajectory of combined pulmonary fibrosis and emphysema.

BACKGROUND Combined pulmonary fibrosis and emphysema (CPFE) is an important phenotype in patients with fibrotic interstitial lung disease (ILD). RESEARCH QUESTIONS (1) What is the prevalence of CPFE? (2) What is the predictive performance of the CPFE Index and of physiological airflow obstruction for computed tomogra...

Y. Khor, Daniel-Costin Marinescu, H. Manganas et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.